2,2'-Dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations.
Domagala Jm(Time Warner (United States)), Thomas J. McQuade(University of Massachusetts Chan Medical School), Michael D. Reily(Pfizer (United States)), Loo J, Sanchez Jp, Jeffrey D. Scholten(Io Therapeutics (United States)), Patricia J. Harvey(University of Greenwich), Peter J. Tummino(Intarcia Therapeutics (United States)), L Sharmeen, Yuntao Song(Chinese Academy of Sciences), Rocco D. Gogliotti(Vanderbilt University), Stier Ma, Donald Hupe(Pfizer (United States)), K Musa, John Saunders, Daniel J. Mack
PubMed
May 1, 1997
Cited by 8
Related Papers
Proposed minimum reporting standards for chemical analysis
|Metabolomics|2007|5k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550